Limits of ¹⁸F-fluorodeoxyglucose positron emission tomography in recurrence diagnosis of borderline ovarian tumor

Int J Gynecol Cancer. 2010 Jul;20(5):694-7. doi: 10.1111/igc.0b013e3181da2912.

Abstract

Most borderline ovarian tumors (BOT) occur in young women and exhibit a low malignant behavior. Nevertheless, an accurate long-term follow-up is required because, frequently, recurrence arises after many years from primary treatment, especially in patients affected by BOT with invasive peritoneal implants, which have a worse prognosis. We report the case of a pelvic recurrence of serous BOT firstly suspected by physical examination but misdiagnosed by ¹⁸F-fluorodeoxyglucose positron emission tomography and computed tomography and identified only by magnetic resonance imaging, 7 years after primary treatment. We also reviewed the literature concerning the role of ¹⁸F-fluorodeoxyglucose positron emission tomography in the management and follow-up of BOT.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Magnetic Resonance Imaging
  • Neoplasm Recurrence, Local / diagnosis*
  • Ovarian Neoplasms / diagnosis*
  • Ovarian Neoplasms / therapy*
  • Positron-Emission Tomography*
  • Pregnancy
  • Pregnancy Complications, Neoplastic / diagnosis*
  • Pregnancy Complications, Neoplastic / therapy*
  • Radiopharmaceuticals*
  • Tomography, X-Ray Computed

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18